Abstract
Background: Cardiac tumors rare cardiac disorders with an overall incidence rate < 0.33%. Cardiac tumors can be classified as primary or secondary depending on the origins of tumors. Primary cardiac tumors (5% incidence) are rare compared with the secondary (95%, metastases of the heart) cardiac tumors.
Objective: Given that cardiac tumors exhibit some nonspecific symptoms compared with other heart diseases, clinical diagnosis of cardiac tumors is rather challenging. Thus we will try to review the classification and pathogenesis of cardiac tumors.
Conclusion: Current evidence revealed that 75% of cardiac tumors are considered benign (myxoma, fibromas, lipomas, rhabdomyomas, hemangiomas, teratomas, papillary fibroelastomas, pericardial cysts or cystic tumor of atrioventricular node). Clinical differential diagnosis of cardiac tumors is mainly based on imaging techniques including transthoracic and transesophageal echocardiograms, computed tomography (CT) scans and magnetic resonance imaging (MRIs). This mini-review tries to summarize recent understanding of the pathogenesis and therapeutics of cardiac tumors.
Keywords: Heart, tumors, therapeutics, benign, malignant, pathogenesis.
Current Drug Targets
Title:Cardiac Tumors: Clinical Perspective and Therapeutic Considerations
Volume: 18 Issue: 15
Author(s): Dylan Y. Ren, Nathan D. Fuller, Sara A.B. Gilbert and Yingmei Zhang*
Affiliation:
- Center for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WY 82071,United States
Keywords: Heart, tumors, therapeutics, benign, malignant, pathogenesis.
Abstract: Background: Cardiac tumors rare cardiac disorders with an overall incidence rate < 0.33%. Cardiac tumors can be classified as primary or secondary depending on the origins of tumors. Primary cardiac tumors (5% incidence) are rare compared with the secondary (95%, metastases of the heart) cardiac tumors.
Objective: Given that cardiac tumors exhibit some nonspecific symptoms compared with other heart diseases, clinical diagnosis of cardiac tumors is rather challenging. Thus we will try to review the classification and pathogenesis of cardiac tumors.
Conclusion: Current evidence revealed that 75% of cardiac tumors are considered benign (myxoma, fibromas, lipomas, rhabdomyomas, hemangiomas, teratomas, papillary fibroelastomas, pericardial cysts or cystic tumor of atrioventricular node). Clinical differential diagnosis of cardiac tumors is mainly based on imaging techniques including transthoracic and transesophageal echocardiograms, computed tomography (CT) scans and magnetic resonance imaging (MRIs). This mini-review tries to summarize recent understanding of the pathogenesis and therapeutics of cardiac tumors.
Export Options
About this article
Cite this article as:
Ren Y. Dylan, Fuller D. Nathan, Gilbert A.B. Sara and Zhang Yingmei*, Cardiac Tumors: Clinical Perspective and Therapeutic Considerations, Current Drug Targets 2017; 18 (15) . https://dx.doi.org/10.2174/1389450117666160703162111
DOI https://dx.doi.org/10.2174/1389450117666160703162111 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inverse Regulation of MMP-9 and MMP-2 in Long-Term Follow-up After Acute Coronary Syndrome: Lack of Correlation with Platelet and Endothelial Cell Activation Markers
Vascular Disease Prevention (Discontinued) The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Potential of Resveratrol in Preventing the Development of Heart Failure
Current Chemical Biology ACE2 and Diabetic Complications
Current Pharmaceutical Design Circadian Rhythm in Cytokines Administration
Mini-Reviews in Medicinal Chemistry Value of Real Time Three Dimensional Transesophageal Echocardiography in General Cardiology Practice
Recent Patents on Medical Imaging Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets Altered Prolylcarboxypeptidase Expression and Function in Response to Different Risk Factors of Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Autophagy in the Gut Pathogens Clearance and Evasion
Current Protein & Peptide Science Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews Calcium Handling and Arrhythmogenesis
Medicinal Chemistry MicroRNA 21 Emerging Role in Diabetic Complications: A Critical Update
Current Diabetes Reviews Editorial [Hot Topic:The Metabolic Treatment of Coronary Artery Disease and Heart Failure(Executive Editor: Pericle Di Napoli)]
Current Pharmaceutical Design Changes in the Expression of the Alzheimers Disease-Associated Presenilin Gene in Drosophila Heart Leads to Cardiac Dysfunction
Current Alzheimer Research Omega-3 Fatty Acid Treatment Combined with Chemotherapy to Prevent Toxicity, Drug Resistance, and Metastasis in Cancer
Current Drug Targets The Pentacyclic Triterpenoids in Herbal Medicines and Their Pharmacological Activities in Diabetes and Diabetic Complications
Current Medicinal Chemistry Prospects of Non-Coding Elements in Genomic DNA Based Gene Therapy
Current Gene Therapy Methods to Evaluate the Inhibition of TTR Fibrillogenesis Induced by Small Ligands
Current Medicinal Chemistry CA125: An Increasingly Promising Biomarker of Heart Failure
Current Pharmaceutical Design